SUNNYVALE, Calif., Dec. 21, 2016 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) has signed an agreement with Hong Kong
Sanatorium & Hospital (HKSH) for the acquisition of three
RadixactTM Systems that will provide clinicians and
their patients with access to the newest advanced radiation
therapy. Of the three Radixact Systems, two will replace existing
TomoTherapy® Systems and one will be installed in a new bunker. The
agreement also includes an upgrade of HKSH's existing CyberKnife®
M6™ System to include the latest features for motion management and
treatment efficiency, and was entered into backlog during Accuray's
second fiscal quarter which ends December
31, 2016.
The agreement with HKSH will make Radixact, the next-generation
helical radiation therapy technology, available for the full range
of cancer patients being treated at this private hospital system
known for high quality patient care based on advanced knowledge,
expertise and technology. The system will enable the HKSH
clinical team to more efficiently and effectively deliver precise
radiation treatments, and to confidently adapt therapy to changes
in tumor size, shape and location — as well as subtle changes in
the location of organs and other healthy tissue.
"HKSH has a well-earned reputation for high-quality patient care
based on advanced knowledge, expertise and technology. We are
honored to expand Accuray's role in helping their team meet the
needs of their rapidly growing patient population. HKSH will
be the first hospital in Asia to
have both the Radixact and CyberKnife M6 Systems available for
patient treatments. This commitment shows confidence in our
new Radixact System and in the Accuray team's ability to help the
Hospital provide 'Quality in Service; Excellence in Care,'" said
Josh Levine, President and Chief
Executive Officer of Accuray.
"We are excited to build on the previous experience we have had
with the TomoTherapy platform by moving to the next generation
helical platform from Accuray. The TomoTherapy platform has
enabled us to treat a wide range of cancer patients. The
CyberKnife M6 and Radixact Systems, together, are complementary
technologies that will enable us to offer each cancer patient the
advanced radiation therapy best suited to precisely treating their
disease while minimizing side effects," said Mr. Wyman Li, Manager (Administration) of HKSH.
"Hong Kong Sanatorium & Hospital has had great success in
the treatment of cancer, the No. 1 cause of death in Hong
Kong. We are excited to build on our initial work with
Accuray to offer state-of-the-art advanced radiation treatments to
patients. The Radixact and CyberKnife M6 Systems' unique
modalities and precision will enable us to meet growing demand for
high quality treatment and will play a key role in the
armamentarium of state-of-the art technologies that form the
backbone of the Hospital's arsenal against cancer," he added.
For more information about the Accuray radiation therapy
systems, visit www.accuray.com.
Important Safety Information
For Important Safety Information please refer to
http://www.accuray.com/safety-statement-radiation-treatment
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company
that develops, manufactures and sells precise, innovative tumor
treatment solutions that set the standard of care with the aim of
helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments. For more information, please
visit www.accuray.com.
About Hong Kong Sanatorium & Hospital
Hong Kong Sanatorium & Hospital (HKSH) is one of the leading
private hospitals in Hong Kong. It is owned by the Li Shu Fan
Medical foundation (LSFMF). HKSH is committed to fulfilling
LSFMF's vision of providing quality health care and advancing
medical education and research, with an overriding concern for the
public good.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, market acceptance of our new technologies,
patient outcomes and Accuray's leadership position in radiation
oncology innovation and technologies. Forward-looking statements
are subject to risks and uncertainties that could cause actual
results to differ materially from expectations, including but not
limited to the risks detailed from time to time under the heading
"Risk Factors" in the company's report on Form 10-K, filed on
August 24, 2016, the company's report
on Form 10-Q, filed on November 1,
2016, and as updated periodically with the company's other
filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Investor Contact:
Doug Sherk
EVC Group
+1 (646) 445-4800
dsherk@evcgroup.com
Media Contacts:
Beth Kaplan
Accuray
+1 (408) 789-4426
bkaplan@accuray.com
Jane Hauser
MSLGROUP
+1 (781) 684-0770
accuray@mslgroup.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/hong-kong-sanatorium--hospital-to-acquire-three-radixacttm-systems-300382339.html
SOURCE Accuray Incorporated